5 Key Takeaways

• 1

  A study investigated 0.01% atropine eye drops as a nonsurgical treatment for symptomatic vitreous floaters.

• 2

  Patients with vitreous syneresis or chronic PVD were prescribed low-dose atropine, with 30% to 60% reporting symptomatic relief.

• 3

  The treatment was well tolerated, with only 18.2% experiencing adverse effects like worsened vision or light sensitivity.

• 4

  Low-dose atropine offers a noninvasive alternative to invasive procedures like vitrectomy for managing floaters.

• 5

  The drops must be prepared by a compounding pharmacy and are not covered by insurance, costing approximately $55 to $65.